TITLE

Self-reported signs of lipodystrophy by persons living with HIV infection

AUTHOR(S)
Dreezen, C.; Schrooten, W.; De Mey, I.; Goebel, F. D.; Dedes, N.; Florence, E.; Colebunders, R.; Eurosupport Study Group
PUB. DATE
June 2002
SOURCE
International Journal of STD & AIDS;Jun2002, Vol. 13 Issue 6, p393
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: To identify risk factors for the development of lipodystrophy in HIV infected patients on highly active antiretroviral therapy.Methods: A survey among patients with HIV infection using an anonymous questionnaire was conducted in 10 European countries between December 1998 and December 1999. Nine hundred and four people receiving antiretrovirals, were included in the analyses.Results: 368 (41%) people reported an increase in abdominal girth since commencing current antiretroviral treatment. Breast enlargement was reported by 106 people (12%). Lipoatrophy signs were reported by approximately one-third of the people: 291 (32%) complained about decrease in facial fat and 300 (33%) reported decrease in buttock fat. One hundred and thirty-one (15%) people reported both lipoatrophy signs and an increase in abdominal girth (mixed lipodystrophy syndrome). In multivariate analysis, the development of the mixed lipodystrophy syndrome was associated with a longer use of indinavir (OR=1.03, 95% CI: 1.00-1.06), ritonavir (OR=1.06, 1.02-1.09) and stavudine (OR=1.05, 1.02-1.08) and also with age, a longer duration of HIV seropositivity and an advanced stage of HIV infection.Conclusions: This study suggests that multiple factors are associated with the occurrence of lipodystrophy, including the prolonged use of protease inhibitors.
ACCESSION #
22203511

 

Related Articles

  • Association between HLA-B*4001 and Lipodystrophy among HIV-Infected Patients from Thailand Who Received a Stavudine-Containing Antiretroviral Regimen. Wangsomboonsiri, Wittaya; Mahasirimongkol, Surakameth; Chantarangsu, Soranun; Kiertiburanakul, Sasisopin; Charoenyingwattana, Angkana; Komindr, Surat; Thongnak, Chupong; Mushiroda, Taisei; Nakamura, Yusuke; Chantratita, Wasun; Sungkanuparph, Somnuek // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, p597 

    Background. Stavudine-containing antiretroviral regimens are widely used in developing countries. Stavudineassociated lipodystrophy commonly occurs, without a clear predictable pattern owing to the unknown interaction between stavudine and the host, among patients who received this regimen. The...

  • Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial. Kolta, Sami; Flandre, Philippe; Van, Philippe Ngo; Cohen-Codar, Isabelle; Valantin, Marc-Antoine; Pintado, Claire; Morlat, Philippe; Boué, Francois; Rode, Richard; Norton, Michael; Knysz, Brygida; Briot, Karine; Roux, Christian; Delfraissy, Jean-François // Current HIV Research;Jan2011, Vol. 9 Issue 1, p31 

    No abstract available.

  • DisfuncÈ›ia endotelială, lipodistrofia ÅŸi sindromul metabolic la pacienÈ›i infectaÈ›i cu HIV. PAPIȚĂ, ANAMARIA; ALBU, ADRIANA; ITU, CORINA; CÂRSTINA, D. // Romanian Journal of Medical Practice;2010, Vol. 5 Issue 3, p185 

    HIV infection has become in our days a chronic disease due to the efficiency of antiretroviral (ARV) treatment. Soon after the introduction of this treatment its complications related to metabolic disturbances have been observed and studied. Metabolic syndrome was particularly described in...

  • Lipoatrophy Is the Predominant Presentation of HIV-Associated Lipodystrophy in Southern India.  // Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p1646 

    At Yrg Care, a nonprofit organization and tertiary referral care center in southern India that provides medical and psychosocial care for nearly 4000 people living with HIV infection, all patients receiving antiretroviral therapy (ART) have had anthropometric measurements taken at each clinic...

  • Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L. // AIDS & Behavior;May2006, Vol. 10 Issue 3, p273 

    Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample...

  • Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial. Gallant, Joel E.; Staszewski, Schlomo; Pozniak, Anton L.; DeJesus, Edwin; Suleiman, Jamal M. A. H.; Miller, Michael D.; Coakley, Dion F.; Lu, Biao; Toole, John J.; Cheng, Andrew K. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p191 

    Context Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants A prospective, randomized,...

  • Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. Steigbigel, Roy T.; Cooper, David A.; Teppler, Hedy; Eron, Joseph J.; Gatell, Jose M.; Kumar, Princy N.; Rockstroh, Jurgen K.; Schechter, Mauro; Katlama, Christine; Markowitz, Martin; Yeni, Patrick; Loutfy, Mona R.; Lazzarin, Adriano; Lennox, Jeffrey L.; Clotet, Bonaventura; Jing Zhao; Hong Wan; Rhodes, Rand R.; Strohmaier, Kim M.; Barnard, Richard J. // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, p605 

    BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background...

  • Treatment of Mycobacterium avium Complex Immune Reconstitution Disease in HIV-1-Infected Individuals. Desimone, Joseph A.; Babinchak, Timothy J.; Kaulback, Kris R.; Pomerantz, Roger J. // AIDS Patient Care & STDs;Dec2003, Vol. 17 Issue 12, p617 

    Immune reconstitution disease caused by Mycobacterium avium complex (MAC) infection presenting shortly after the introduction of highly active antiretroviral therapy (HAART) has been reported with increasing frequency in persons with HIV-1 infection during the past several years. Several...

  • Predictors of Virological Outcome and Safety in Primary HIV Type 1—Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Hoen, Bruno; Cooper, David A.; Lampe, Fiona C.; Perrin, Luc; Clumeck, Nathan; Phillips, Andrew N.; Goh, Li-Ean; Lindback, Stefan; Sereni, Daniel; Gazzard, Brian; Montaner, Julio; Stellbrink, Hans-Jurgen; Lazzarin, Adriano; Ponscarme, Diane; Staszewski, Shlomo; Mathiesen, Lars; Smith, Don; Finlayson, Robert; Weber, Rainer; Wegmann, Laurence // Clinical Infectious Diseases;8/1/2007, Vol. 45 Issue 3, p381 

    Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit. Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics